Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States.
Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States.
Inflamm Bowel Dis. 2022 Dec 1;28(12):1833-1837. doi: 10.1093/ibd/izac011.
Up to one-third of patients hospitalized for acute severe colitis secondary to inflammatory bowel diseases (IBD) do not adequately respond to intravenous steroids. There is an unmet need to identify a useful predictor for rescue treatment in this cohort of patients.
The aim of this study was to assess the predictive efficacy of fecal calprotectin in identifying the need for medical or surgical therapy in patients with acute severe colitis.
We conducted a multicenter retrospective cohort study including patients with ulcerative colitis (UC) who were hospitalized for severe exacerbation of colitis. The primary outcome was the need for in-hospital medical or surgical rescue therapy. Univariate and multivariate logistic regression was performed to identify predictors of rescue therapy.
Our study included 147 patients with UC. One-third (33%) required rescue therapy, and 13% underwent colectomy. Patients requiring rescue therapy had significantly higher fecal calprotectin (mean 1748 mcg/g vs 1353 mcg/g, P = .02) compared with those who did not. A fecal calprotectin >800 mcg/g independently predicted the need for inpatient medical rescue therapy (odds ratio, 2.61; 95% CI, 1.12-6.12). An admission calprotectin >800 mcg/g independently predicted surgery within 3 months (odds ratio, 2.88; 95% CI, 1.01-8.17).
Fecal calprotectin levels may serve as a useful noninvasive predictor of medical and surgical risk in individuals with UC presenting with acute severe colitis. This approach can facilitate earlier therapeutic interventions and improve outcomes.
多达三分之一因炎症性肠病(IBD)导致急性重度结肠炎而住院的患者对静脉注射类固醇治疗反应不佳。在这一患者群体中,需要找到一种有用的预测因子来识别需要挽救性治疗的患者。
本研究旨在评估粪便钙卫蛋白在识别急性重度结肠炎患者是否需要接受药物或手术治疗方面的预测效果。
我们进行了一项多中心回顾性队列研究,纳入因结肠炎恶化而住院的溃疡性结肠炎(UC)患者。主要结局是需要住院接受药物或手术挽救性治疗。采用单变量和多变量逻辑回归分析来识别挽救性治疗的预测因子。
本研究共纳入 147 例 UC 患者。三分之一(33%)的患者需要挽救性治疗,13%的患者接受了结肠切除术。需要挽救性治疗的患者粪便钙卫蛋白显著更高(平均值为 1748 mcg/g 比 1353 mcg/g,P =.02)。粪便钙卫蛋白>800 mcg/g 独立预测需要住院接受药物挽救性治疗(比值比,2.61;95%置信区间,1.12-6.12)。入院时钙卫蛋白>800 mcg/g 独立预测 3 个月内需要手术(比值比,2.88;95%置信区间,1.01-8.17)。
粪便钙卫蛋白水平可能是预测 UC 患者急性重度结肠炎是否需要药物和手术治疗的有用非侵入性预测因子。这种方法可以促进更早的治疗干预,并改善结局。